Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Drug Lag Attributable to Delay in Starting Clinical Trials: OPIR Study
October 13, 2008
- REGULATORY NEWS IN BRIEF
October 13, 2008
- NEW PRODUCTS
October 13, 2008
- Original and Generic Amlodipine Products Show Same Effects
October 13, 2008
- Kyowa Hakko Kirin Sets Out Aiming at Becoming Global Specialty Pharma
October 13, 2008
- GENERICS NEWS IN BRIEF
October 13, 2008
- Argatroban to Be Temporarily Excluded from DPC Payment
October 6, 2008
- Levemir Reduces Risk of Nocturnal Hypoglycemia: Novo Nordisk
October 6, 2008
- Tamiflu Ban in Teenagers Should Not Be Lifted: Medwatcher Japan
October 6, 2008
- H. Pylori Eradication Should Be Covered by Health Insurance
October 6, 2008
- Chuikyo to Continue Discussions on NHI Pricing System Reform Proposed by Industry
October 6, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 6, 2008
- FPMAJ Explains Its NHI Pricing System Reform Proposal
October 6, 2008
- Teva Ties Up with Kowa to Fully Enter Japanese Market for Generics
October 6, 2008
- New Prime Minister Taro Aso Reappoints Yoichi Masuzoe as Health Minister
October 6, 2008
- JT Licenses Oral Drug for Osteoporosis to Merck of the US
October 6, 2008
- Takeda Applies for Alogliptin/ACTOS Combination in the US
October 6, 2008
- All of the Top Five Drugs Were ARBs in August: Rep Track Survey
October 6, 2008
- REGULATORY NEWS IN BRIEF
October 6, 2008
- Alfresa HD Ties Up with Medical System Network
October 6, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…